Recent advances and current challenges in tumor immunology and immunotherapy

Barbara Ann Guinn, Noriyuki Kasahara, Farzin Farzaneh, Nagy A. Habib, James S. Norris, Albert B. Deisseroth

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Despite advances in animal studies, where the cure of the majority of mice with pre-established (albeit early-stage) tumors has become almost standard, human clinical trials have been much less successful. Here we describe some of the most recent advances in the specialist field of tumor immunology and immunotherapy, highlighting salient work to identify key problem areas and potential solutions. We make particular note of recent developments in adoptive therapy; whole-cell, DNA, and peptide vaccines; and antibody therapy. We also describe the revival of interest in regulatory T cells and conclude by detailing the need for clinical trial read-out autonomy and methods to predict which patients will respond to a particular treatment.

Original languageEnglish (US)
Pages (from-to)1065-1071
Number of pages7
JournalMolecular Therapy
Volume15
Issue number6
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Allergy and Immunology
Immunotherapy
Clinical Trials
Neoplasms
Subunit Vaccines
DNA Vaccines
Regulatory T-Lymphocytes
Therapeutics
Antibodies

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Guinn, B. A., Kasahara, N., Farzaneh, F., Habib, N. A., Norris, J. S., & Deisseroth, A. B. (2007). Recent advances and current challenges in tumor immunology and immunotherapy. Molecular Therapy, 15(6), 1065-1071. https://doi.org/10.1038/sj.mt.6300138

Recent advances and current challenges in tumor immunology and immunotherapy. / Guinn, Barbara Ann; Kasahara, Noriyuki; Farzaneh, Farzin; Habib, Nagy A.; Norris, James S.; Deisseroth, Albert B.

In: Molecular Therapy, Vol. 15, No. 6, 06.2007, p. 1065-1071.

Research output: Contribution to journalArticle

Guinn, BA, Kasahara, N, Farzaneh, F, Habib, NA, Norris, JS & Deisseroth, AB 2007, 'Recent advances and current challenges in tumor immunology and immunotherapy', Molecular Therapy, vol. 15, no. 6, pp. 1065-1071. https://doi.org/10.1038/sj.mt.6300138
Guinn, Barbara Ann ; Kasahara, Noriyuki ; Farzaneh, Farzin ; Habib, Nagy A. ; Norris, James S. ; Deisseroth, Albert B. / Recent advances and current challenges in tumor immunology and immunotherapy. In: Molecular Therapy. 2007 ; Vol. 15, No. 6. pp. 1065-1071.
@article{489d0a63fc0d4b27826c2cd2769416dd,
title = "Recent advances and current challenges in tumor immunology and immunotherapy",
abstract = "Despite advances in animal studies, where the cure of the majority of mice with pre-established (albeit early-stage) tumors has become almost standard, human clinical trials have been much less successful. Here we describe some of the most recent advances in the specialist field of tumor immunology and immunotherapy, highlighting salient work to identify key problem areas and potential solutions. We make particular note of recent developments in adoptive therapy; whole-cell, DNA, and peptide vaccines; and antibody therapy. We also describe the revival of interest in regulatory T cells and conclude by detailing the need for clinical trial read-out autonomy and methods to predict which patients will respond to a particular treatment.",
author = "Guinn, {Barbara Ann} and Noriyuki Kasahara and Farzin Farzaneh and Habib, {Nagy A.} and Norris, {James S.} and Deisseroth, {Albert B.}",
year = "2007",
month = "6",
doi = "10.1038/sj.mt.6300138",
language = "English (US)",
volume = "15",
pages = "1065--1071",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Recent advances and current challenges in tumor immunology and immunotherapy

AU - Guinn, Barbara Ann

AU - Kasahara, Noriyuki

AU - Farzaneh, Farzin

AU - Habib, Nagy A.

AU - Norris, James S.

AU - Deisseroth, Albert B.

PY - 2007/6

Y1 - 2007/6

N2 - Despite advances in animal studies, where the cure of the majority of mice with pre-established (albeit early-stage) tumors has become almost standard, human clinical trials have been much less successful. Here we describe some of the most recent advances in the specialist field of tumor immunology and immunotherapy, highlighting salient work to identify key problem areas and potential solutions. We make particular note of recent developments in adoptive therapy; whole-cell, DNA, and peptide vaccines; and antibody therapy. We also describe the revival of interest in regulatory T cells and conclude by detailing the need for clinical trial read-out autonomy and methods to predict which patients will respond to a particular treatment.

AB - Despite advances in animal studies, where the cure of the majority of mice with pre-established (albeit early-stage) tumors has become almost standard, human clinical trials have been much less successful. Here we describe some of the most recent advances in the specialist field of tumor immunology and immunotherapy, highlighting salient work to identify key problem areas and potential solutions. We make particular note of recent developments in adoptive therapy; whole-cell, DNA, and peptide vaccines; and antibody therapy. We also describe the revival of interest in regulatory T cells and conclude by detailing the need for clinical trial read-out autonomy and methods to predict which patients will respond to a particular treatment.

UR - http://www.scopus.com/inward/record.url?scp=34249321620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249321620&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300138

DO - 10.1038/sj.mt.6300138

M3 - Article

C2 - 17375068

AN - SCOPUS:34249321620

VL - 15

SP - 1065

EP - 1071

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -